Phibro Animal Health Corp Liquidation Value

PAHC Pharmaceuticals

Cash & Equivalents

$54.93M
As of 2026-03-31
Current Price: N/A

Key Metrics

Cash Liquidation Value

Cash minus Total Obligations
Cash: $54.93M
Total Obligations: -$922.06M
$-867.13M
Per share: $-21.39
Period: 2026-03-31
incomplete 1 component missing — treated as $0 in formula. Why?
  • Operating Lease Liability: not reported in this period (annual-only)

Liquid Liquidation Value

Cash + AR minus Total Obligations
Cash: $54.93M
AR: $221.55M
Total Obligations: -$922.06M
$-645.59M
Per share: $-15.92
Period: 2026-03-31
incomplete 1 component missing — treated as $0 in formula. Why?
  • Operating Lease Liability: not reported in this period (annual-only)

Operating Liquidation Value

Cash + AR + Inventory minus Total Obligations
Cash: $54.93M
AR: $221.55M
Inventory: $539.70M
Total Obligations: -$922.06M
$-105.89M
Per share: $-2.61
Period: 2026-03-31
incomplete 1 component missing — treated as $0 in formula. Why?
  • Operating Lease Liability: not reported in this period (annual-only)

Build your own liquidation scenario

Adjust asset discounts and liability assumptions to see how assumptions affect the numbers.

Open Calculator →

Liquidation Ladder

MetricTotalPer Share
Cash Liquidation Value$-867.13M$-21.39
Liquid Liquidation Value$-645.59M$-15.92
Operating Liquidation Value$-105.89M$-2.61

Key Components (as of 2026-03-31)

Data as of 2026-03-31 from 10-Q filed 2026-05-06. View on SEC EDGAR →

Cash & Equivalents$54.93M
Accounts Receivable$221.55M
Inventory$539.70M
Current Liabilities$281.87M
Long-term Debt (?)$597.68M
Op. Lease Liability (?)$42.51M
Finance Lease (?)N/A
Shares Outstanding40.5M

Explore all 122 XBRL tags and build your own scenario → Open Calculator

Historical

PeriodCashARInventoryAPCurr LiabLT DebtOp LeaseFin Lease
2026-03-31$54.93M$221.55M$539.70M$129.64M$281.87M$597.68M$42.51MN/A
2025-12-31$55.49M$215.87M$517.35M$133.30M$282.37M$603.60M$32.97MN/A
2025-09-30$72.77M$217.90M$471.77M$130.60M$270.14M$609.52M$33.12MN/A
2025-06-30$68.04M$227.98M$444.43M$138.20M$293.47M$615.43M$33.74MN/A
2025-03-31$60.35M$197.52M$448.39M$131.62M$266.48M$619.16M$33.63MN/A
2024-12-31$67.07M$191.79M$427.22M$99.44M$233.25M$622.88M$28.32MN/A
2024-09-30$51.84M$160.78M$272.56M$86.53M$176.89M$287.67M$29.82MN/A
2024-06-30$70.61M$169.45M$265.91M$85.57M$204.15M$282.29M$29.91MN/A

Comments

SEC Filings

PeriodFormFiledLink
2026-03-31 10-Q 2026-05-06 View
2025-12-31 10-Q 2026-02-04 View
2025-09-30 10-Q 2025-11-05 View
2025-06-30 10-K 2025-08-27 View
2025-03-31 10-Q 2025-05-07 View
2024-12-31 10-Q 2025-02-05 View
2024-09-30 10-Q 2024-11-06 View
2024-06-30 10-K 2024-08-28 View

AI Insights

AI Insight·Generated 2026-05-09

PAHC's liquidation posture as of March 31, 2026 remains deeply negative, consistent with MFFAIS CLV of approximately -$867M and LLV of approximately -$646M. The balance sheet carries $1.445B in total assets against $1.083B in total liabilities, yielding GAAP book equity of $362M. Under liquidation haircuts, however, recoverable asset value collapses materially. Cash and short-term investments of $77.5M recover near par. Accounts receivable of $222M at 90-95% haircut yields approximately $199-210M. Inventory of $540M is the single largest current asset and at a 60% recovery rate yields approximately $324M — but the nine-month operating period consumed $92.5M of inventory build, suggesting elevated carrying values relative to near-term turnover. PP&E net book value of $359M at 50-70% recovery yields approximately $180-251M. The intangible stack — $31.7M finite-lived intangibles, $59.9M goodwill, plus additional acquisition-related embedded step-up values — is zeroed under the lens. The total gross term debt carrying amount is $626M (current $22.8M plus non-current $598M), with $115M outstanding on the revolving facility also included in the $621M long-term debt figure. On April 28, 2026, PAHC expanded the revolver by $125M to $435M total capacity — a post-period event that increases the available liability stack in a wind-up scenario without adding tangible recoverable assets. Operating lease obligations total approximately $52M ($9.4M current, $42.5M non-current) and must be settled at face value in liquidation. The environmental accrual of $4.2M is a minimum floor; actual wind-up environmental remediation liabilities for a multi-site pharmaceutical manufacturer would likely exceed this figure materially. The MFA portfolio acquisition from Zoetis (closed October 31, 2024) drove $156.8M in incremental nine-month revenues and added significant acquired PP&E subject to step-up depreciation ($5.0M over nine months) and intangible amortization. The acquisition-related cost structure increases both the tangible PP&E base and the intangible stack (zeroed under the lens), making the liquidation-vs.-going-concern divergence wider post-acquisition. Nine-month operating cash generation of $44.9M versus $58.9M in the prior comparable period reflects $92.5M of inventory accumulation — a use of cash that inflates the balance sheet at a haircut-subject rate. The filing does not separately disclose undrawn letters of credit or environmental indemnification exposure beyond the $4.2M accrual, both of which are contingent liabilities that could further erode recovery. Working capital (as company-defined, excluding cash and current debt) expanded to $558M from $456M at June 30, 2025, driven primarily by the inventory build. Under the liquidation lens, this working capital expansion represents incremental haircut exposure, not recoverable value enhancement.

Flags

Loading flags...

AI Insight Discussion

Loading...

Community Notes

Loading notes...

Questions

Loading questions...